The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
Open accessAbstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co‐primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within ATM, BRCA1/ 2, Rb1, or TP53. The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio [HR], 0.44; 95% CI, 0.29 to 0.66; P value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk, 0.05; HR no high-risk, 0.42; P value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; P = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372
Ost, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., Lambert, B., Delrue, L., Bultijnck, R., Claeys, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4853 · Cited by 1,351
Self-citationPhillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., Rowe, S. P., Ross, A. E., Gorin, M. A., Deville, C., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0147 · Cited by 1,159
Self-citationCastro, E., Goh, C., Olmos, D., Saunders, E., Leongamornlert, D., Tymrakiewicz, M., Mahmud, N., Dadaev, T., Govindasami, K., Guy, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1882 · Cited by 850
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
Gallagher, D. J., Gaudet, M. M., Pal, P., Kirchhoff, T., Balistreri, L., Vora, K., Bhatia, J., Stadler, Z., Fine, S. W., Reuter, V., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2871 · Cited by 301
MicroRNA Expression Characterizes Oligometastasis(es)
Lussier, Y. A., Xing, H. R., Salama, J. K., Khodarev, N. N., Huang, Y., Zhang, Q., Khan, S. A., Yang, X., Hasselle, M. D., Darga, T. E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028650 · Cited by 281
Pitroda, S. P., Khodarev, N. N., Huang, L., Uppal, A., Wightman, S. C., Ganai, S., Joseph, N., Pitt, J., Brown, M., Forde, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04278-6 · Cited by 254
Lussier, Y. A., Khodarev, N. N., Regan, K., Corbin, K., Li, H., Ganai, S., Khan, S. A., Gnerlich, J., Darga, T. E., Fan, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050141 · Cited by 201
Wong, A., Watson, S. P., Pitroda, S. P., Son, C. H., Das, L. C., Stack, M. E., Uppal, A., Oshima, G., Khodarev, N. N., Salama, J. K., et al. (2016) · Cancer · doi:10.1002/cncr.30058 · Cited by 138
Deek, M. P., der Eecken, K. V., Phillips, R., Parikh, N. R., Velho, P. I., Lotan, T. L., Kishan, A. U., Maurer, T., Boutros, P. C., Hovens, C. M., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.12.040 · Cited by 106
Self-citationRare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study
Karlsson, Q., Brook, M. N., Dadaev, T., Wakerell, S., Saunders, E. J., Muir, K. R., Neal, D. E., Giles, G. G., MacInnis, R. J., Thibodeau, S. N., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2020.12.001 · Cited by 93
Integrated molecular and clinical staging defines the spectrum of metastatic cancer
Pitroda, S. P., & Weichselbaum, R. R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0220-6 · Cited by 59
der Eecken, K. V., Vanwelkenhuyzen, J. P., Deek, M. P., Tran, P. T., Warner, E. W., Wyatt, A. W., Kwan, E. M., Verbeke, S., Dorpe, J. V., Fonteyne, V., et al. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.10.005 · Cited by 43
Self-citationHasan, H., Deek, M. P., Phillips, R., Hobbs, R. F., Malek, R. A., Radwan, N., Kiess, A. P., Dipasquale, S., Huang, J. G., Caldwell, T. G., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07000-2 · Cited by 31
Self-citationOnderdonk, B. E., Gutiontov, S. I., & Chmura, S. J. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.09.003 · Cited by 14
Cited by
Tilki, D., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.04.010 · Cited by 352
Self-citationFrancolini, G., Allegra, A. G., Detti, B., Di Cataldo, V., Caini, S., Bruni, A., Ingrosso, G., D'Angelillo, R. M., Alitto, A. R., Augugliaro, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00985 · Cited by 139
Wang, J. H., Deek, M. P., Mendes, A. A., Song, Y., Shetty, A., Bazyar, S., Van der Eecken, K., Chen, E., Showalter, T. N., Royce, T. J., et al. (2025) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110618 · Cited by 25
Self-citation
Metadata
- Authors
- Deek, M. P., Van der Eecken, K., Sutera, P., Deek, R. A., Fonteyne, V., Mendes, A. A., Decaestecker, K., Kiess, A. P., Lumen, N., Phillips, R., De Bruycker, A., Mishra, M., Rana, Z., Molitoris, J., Lambert, B., Delrue, L., Wang, H., Lowe, K., Verbeke, S., Van Dorpe, J., Bultijnck, R., Villeirs, G., De Man, K., Ameye, F., Song, D. Y., DeWeese, T., Paller, C. J., Feng, F. Y., Wyatt, A., Pienta, K. J., Diehn, M., Bentzen, S. M., Joniau, S., Vanhaverbeke, F., De Meerleer, G., Antonarakis, E. S., Lotan, T. L., Berlin, A., Siva, S., Ost, P., & Tran, P. T.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-10-10
- Volume
- 40
- Issue
- 29
- Pages
- 3377-3382
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4292978844
- Cited by
- 260
- References
- 15
- FWCI
- 29.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.